Seegene unveils CURECA, a fully automated PCR solution, earning global acclaim at ESCMID Global 2025 for redefining diagnostics through modular lab automation.
 |
| Seegene’s CURECA debuts at ESCMID 2025 as a transformative PCR automation system, integrating pre-treatment, testing, and analysis in a flexible modular design. Image: Seegene |
Seoul, South Korea — May 3, 2025:
Seegene Inc., a global leader in molecular diagnostics (MDx), captured international attention at ESCMID Global 2025 in Vienna, Austria, with the unveiling of its new conceptual automation platform, CURECA. Presented via a detailed conceptual video, CURECA was praised by experts for its potential to transform the entire PCR diagnostics process — from initial sample handling to final result analysis.
With over 2,300 attendees—including key figures from Italy, Spain, Germany, France, and Canada—Seegene's booth became a standout destination at the conference. Many in the clinical diagnostics field viewed the technology as a possible "game changer" for laboratories seeking to eliminate manual bottlenecks and reduce dependence on highly trained personnel.
CURECA offers a fully automated, end-to-end PCR testing process and is designed to handle a variety of specimen types such as stool, urine, blood, and sputum. One of its core innovations is the Customizable Pre-treatment System (CPS), which automates the loading and processing of primary sample tubes—typically one of the most labor-intensive steps in the molecular diagnostics workflow.
Experts highlighted CPS's ability to drastically reduce human error and enhance operational throughput. “This level of automation is transformative and unlike anything on the market today,” said one attendee. Others noted its potential to streamline daily operations for sexually transmitted infection (STI) testing, which often involves complex specimen handling.
Complementing CPS, Seegene also introduced the Primary Sample Aliquot System (PAS) for cases where pre-treatment is unnecessary. Both CPS and PAS are part of a broader modular concept known as CEFA (Customizable & Expandable Full Automation). This system enables laboratories to build workflows that suit their specific needs by combining different modules or deploying CURECA as a comprehensive solution.
“The modular architecture of CURECA allows labs to optimize space, reduce turnaround times, and increase diagnostic accuracy,” said Young-Seag Baeg, Head of Strategy and Planning at Seegene. “Whether for large hospitals or mid-sized clinics, it’s designed to meet diverse operational requirements.”
Seegene’s CEO, Jong-Yoon Chun, called the response to CURECA a validation of the company’s commitment to driving the future of diagnostics. “The enthusiastic reception at ESCMID underscores the global demand for scalable, intelligent, and space-efficient diagnostic systems,” he said.
The company confirmed it will continue showcasing CURECA at future international events, including ADLM 2025 in Chicago, offering healthcare professionals a closer look at the physical system and potential for collaboration.
All comments cited in this article were based on actual interviews conducted at ESCMID 2025. Names have been changed to preserve privacy per the participants' requests.